
* For depressed adult patients with atypical depression (patients experience overeating,
oversleeping, severely low energy, marked sensitivity to personal rejection).
* Offers treatment with Cymbalta (generic name duloxetine), a recently marketed
antidepressant that has a dual mode of action.
* Participants in this 8-week study are eligible for 3 months of follow-up.
* All study treatment, including visits with a psychiatrist and study medication, is
provided at NO COST to participants.
· For adult patients with a history of poor response to antidepressants
· Includes a careful history of psychiatric illness and prior treatment
· Offers a series of treatment trials until depression is relieved:
(1) Standard dose of a marketed monoamine oxidase inhibitor antidepressant (MAOI)
(2) MAOI above the usual maximum dose
(3) Addition of dextroamphetamine (a stimulant)
(4) Addition of thyroid hormone
· Study medication provided at no cost for 8 to 39 weeks
· For depressed adult patients
· Includes testing with three measures of brain functioning: paper and pencil, hearing,
and vision>BR>
· Offers sequential trials of three treatments: Tofranil (imipramine), Prozac
(fluoxetine), and placebo (an inactive substance, such as a sugar pill)
· Patients who respond to treatment may remain on the same treatment
· Patients who do not respond to treatment are switched to another treatment
· Study medication provided at no cost for 6 to 24 weeks
· For depressed adult patients
· Includes testing with three measures of brain functioning: memory and cognition testing, hearing testing, and Functional Magnetic Resonance Imaging (f-MRI; to assess brain activity)
· Offers a series of treatment trials with three standard antidepressant medications until depression ceases:
(1) Lexapro (escitalopram)
(2) Wellbutrin (bupropion)
(3) Tofranil (imipramine)
· Study medication provided at no cost for 8 to 28 weeks
· For depressed adult patients with marijuana dependence
· Offers 12 weeks of individual counseling at no cost
· Patients receive Effexor (venlafaxine) or placebo (an inactive substance, such as a sugar pill) at no cost for 12 weeks
· For HIV positive adult patients with significant fatigue who are taking antiretroviral medication
· Offers 12 weeks of treatment at no cost with Provigil (modafinil), an approved medication for wakefulness in patients with excessive daytime sleepiness due to narcolepsy
· Patients meet with psychiatrist weekly or biweekly
· For physically healthy adolescents and young adults with long-standing temper outbursts and irritable mood swings with or without marijuana use
· Patients receive six weeks of Depakote (divalproex sodium) or placebo (an inactive substance, such as a sugar pill) at no cost and then receive six weeks of Depakote depending on response
· Individual drug counseling provided at no cost
· For physically healthy children with temper outbursts and irritability
· Patients receive six weeks’ treatment successively with Depakote (divalproex sodium) and placebo (an inactive substance, such as a sugar pill) in either order at no cost
· If medication is helpful, long-term treatment and follow-up is provided at no cost, including medication, if patient’s parents do not have a prescription plan
Approved by the New York State Psychiatric Institute Institutional Review Board 12/10/04-06/17/05
